Literature DB >> 23350787

Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy.

Carla L Ellis1, Patrick C Walsh, Alan W Partin, Jonathan I Epstein.   

Abstract

OBJECTIVE: To establish whether the good prognosis of Gleason score 6 (GS6) is maintained in the setting of multiple involved cores. PATIENTS AND METHODS: In total, 6156 men (from 1 April 2000 to 30 April 2007) with GS6 on biopsy underwent radical prostatectomy (RP) at our institution. The number of positive cores was correlated with the outcome at RP.
RESULTS: More positive cores correlated with less organ-confined disease (P < 0.001), positive margins (P < 0.012), increasing RP grade (P < 0.001) and increased seminal vesicles/lymph node involvement (P = 0.012). For men with data available, the actuarial risk of being biochemically free of disease at 5 years was 93.2% when ≤6 cores were positive (812 men followed to 5 years) vs 89.1% if >6 cores were positive (41 men followed to 2 years) (P = 0.6). Although the predicted 'cure rate' of >75% probability of a tumour showing no evidence of biochemical recurrence at 10 years after RP was statistically different between cases with ≤6 vs >6 positive cores (P < 0.0001), the outcome in both groups was still favourable (90.5% vs 84%). Partin-like tables were generated factoring in the number of positive cores to predict organ-confined disease as a guide for urologists to perform nerve-sparing surgery. For example, with T1c disease, there was a ≥75% probability of organ-confined disease with one to three positive cores regardless of prostate-specific antigen (PSA) level, and the same probability was present with four to six positive cores and a PSA level of 0-4 ng/mL.
CONCLUSION: A low Gleason score on biopsy is a powerful prognostic finding, such that this favourable outcome is maintained even in the setting of multiple positive cores with GS6.
© 2013 BJU International.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23350787      PMCID: PMC3978182          DOI: 10.1111/j.1464-410X.2012.11680.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.

Authors:  Ying Huang; Sumit Isharwal; Alexander Haese; Felix K H Chun; Danil V Makarov; Ziding Feng; Misop Han; Elizabeth Humphreys; Jonathan I Epstein; Alan W Partin; Robert W Veltri
Journal:  BJU Int       Date:  2010-09-28       Impact factor: 5.588

2.  Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications.

Authors:  Stephen J Freedland; Christopher J Kane; Christopher L Amling; William J Aronson; Martha K Terris; Joseph C Presti
Journal:  Urology       Date:  2007-03       Impact factor: 2.649

3.  The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.

Authors:  Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

4.  Prostate cancer volume at biopsy predicts clinically significant upgrading.

Authors:  Fei Dong; J Stephen Jones; Andrew J Stephenson; Cristina Magi-Galluzzi; Alwyn M Reuther; Eric A Klein
Journal:  J Urol       Date:  2008-01-22       Impact factor: 7.450

5.  Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer.

Authors:  Makoto Ohori; Michael W Kattan; Hideshige Koh; Norio Maru; Kevin M Slawin; Shahrokh Shariat; Masatoshi Muramoto; Victor E Reuter; Thomas M Wheeler; Peter T Scardino
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

6.  Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy.

Authors:  Stephen A Boorjian; R Jeffrey Karnes; Laureano J Rangel; Eric J Bergstralh; Michael L Blute
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

7.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.

Authors:  Misop Han; Alan W Partin; Marianna Zahurak; Steven Piantadosi; Johnathan I Epstein; Patrick C Walsh
Journal:  J Urol       Date:  2003-02       Impact factor: 7.450

8.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

9.  Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.

Authors:  Matthias May; Nina Knoll; Michael Siegsmund; Dirk Fahlenkamp; Horst Vogler; Bernd Hoschke; Oliver Gralla
Journal:  J Urol       Date:  2007-09-17       Impact factor: 7.450

Review 10.  Pelvic lymph node irradiation for prostate cancer: who, why, and when?

Authors:  Dian Wang; Colleen Lawton
Journal:  Semin Radiat Oncol       Date:  2008-01       Impact factor: 5.934

  10 in total
  4 in total

1.  Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer.

Authors:  Tatsuo Gondo; Bing Ying Poon; Kazuhiro Matsumoto; Melanie Bernstein; Daniel D Sjoberg; James A Eastham
Journal:  BJU Int       Date:  2014-08-13       Impact factor: 5.588

2.  PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.

Authors:  Sungmin Woo; Sang Youn Kim; Joongyub Lee; Seung Hyup Kim; Jeong Yeon Cho
Journal:  Eur Radiol       Date:  2016-02-04       Impact factor: 5.315

3.  Prostate-specific antigen 10-20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy Gleason score 6.

Authors:  Glen Denmer R Santok; Ali Abdel Raheem; Lawrence Hc Kim; Kidon Chang; Trenton Gh Lum; Byung Ha Chung; Young Deuk Choi; Koon Ho Rha
Journal:  Investig Clin Urol       Date:  2017-02-15

4.  PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.

Authors:  Tamara L Lotan; Filipe Lf Carvalho; Sarah B Peskoe; Jessica L Hicks; Jennifer Good; Helen Fedor; Elizabeth Humphreys; Misop Han; Elizabeth A Platz; Jeremy A Squire; Angelo M De Marzo; David M Berman
Journal:  Mod Pathol       Date:  2014-07-04       Impact factor: 7.842

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.